Protas, Duke and CTTI on clinical trials for diverse populations in the US

A new article co-authored by Protas, Duke Clinical Research Institute (DCRI), Duke-Margolis Institute for Health Research and Clinical Trials Transformation Initiative (CTTI) explores how to improve the evidence generated through clinical trials in the United States, to inform the care of diverse populations. 

The COVID-19 pandemic exposed limitations in US-based clinical trials. While they should efficiently generate reliable and relevant evidence for the populations that will use the studied treatments in the real world, in reality, they often fall short. 

The article, published in Trials, explores how improving research access and making trial participation easier will benefit evidence generation. And to achieve this, the US needs a modern trial infrastructure that broadens research into more routine practice. 

Through the lens of developing medical products – including drugs, devices and biologics – the article examines current barriers, opportunities for advancement and the actions needed to make this modern infrastructure a reality in the US, with the aim of the approach being applicable to countries around the world. 

Read the full article on Trials here. 

Protas and DCRI formed a strategic collaboration in May 2023. Our aim is to transform clinical research by radically changing the way trials are designed and delivered, to better meet the needs of patients and society.

Discover more about Protas’ collaboration with DCRI here.